![]() Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. | ![]() Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. | ||
Founding Date | Founding Date 1863 | Founding Date 1982 | Founding Date 2016 |
Type | Type Public | Type Subsidiary | Type Subsidiary |
Tags | |||
Locations | Locations Morris Plains, US HQ | Locations Irvine, US HQ Basel, CH | |
Employees | Employees 92,8152% decrease | Employees 104 | Employees 3950% increase |
Financial | |||
Revenue (est.) | Revenue (est.) €46.6b (FY, 2024) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A |
Cost of goods | Cost of goods €12b (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €35.8b (FY, 2024) | Gross profit $295k (FY, 2019) | Gross profit N/A |
Net income | Net income (€2.5b) (FY, 2024) | Net income ($357.3m) (FY, 2019) | Net income ($146.7m) (FY, 2020) |
Funding | |||
Total funding raised | Total funding raised $ 3.5b | Total funding raised $ 30m | Total funding raised N/A |
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyUrovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.
View company